Atara Biotherapeutics Announces Plans To Submit Tab-cel BLA In Q2 2024 Following FDA Agreement On Comparability
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics has announced its plans to submit a Biologics License Application (BLA) for Tab-cel in Q2 2024. This decision follows an agreement with the FDA on comparability.
September 19, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atara Biotherapeutics' announcement to submit a BLA for Tab-cel in Q2 2024 could potentially boost investor confidence in the company's pipeline.
The announcement of Atara Biotherapeutics' plans to submit a BLA for Tab-cel in Q2 2024 following an agreement with the FDA on comparability is a positive development for the company. This could potentially boost investor confidence in the company's pipeline and lead to a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100